Hu Zhansheng, Gu Zhilong, Sun Meina, Zhang Ke, Gao Penghui, Yang Qinwu, Yuan Yuan
Department of Critical Care Medicine, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning, People's Republic of China.
Department of Critical Care Medicine, Graduate School of Liaoning Medical University, Jinzhou, Liaoning, People's Republic of China.
J Surg Res. 2015 Apr;194(2):528-536. doi: 10.1016/j.jss.2014.10.027. Epub 2014 Oct 22.
BACKGROUND: Sepsis is characterized as a systemic inflammatory response syndrome during infection, which can result in multiple organ dysfunction and death. Ursolic acid (UA), a pentacyclic triterpene acid, has been reported to have potent anti-inflammatory and antioxidant properties. The aim of this study was to detect the possible protective effects of UA on sepsis-evoked acute lung injury. MATERIALS AND METHODS: A rat model of sepsis induced by cecal ligation and puncture (CLP) was used. Rats were injected intraperitoneally with UA (10 mg/kg) after CLP, and then the survival was determined twice a day for 4 d. The protective effects of UA on CLP-induced acute lung injury were assayed at 24 h after CLP. RESULTS: The results revealed that UA treatment markedly improved the survival of septic rats, and attenuated CLP-induced lung injury, including reduction of lung wet/dry weight ratio, infiltration of leukocytes and proteins, myeloperoxidase activity, and malondialdehyde content. In addition, UA significantly decreased the serum levels of tumor necrosis factor-α, interleukin-6, and interleukin-1β, inhibited the expression of inducible nitric oxide synthase and cyclooxygenase-2 in the lung, which are involved in the productions of nitric oxide and prostaglandin E2. CONCLUSIONS: These findings indicate that UA exerts protective effects on CLP-induced septic rats. UA may be a potential therapeutic agent against sepsis.
J Surg Res. 2015-12
Eur Rev Med Pharmacol Sci. 2017-4
J Surg Res. 2011-12-24
J Surg Res. 2015-2
Medicina (Kaunas). 2021-11-18
Am J Physiol Lung Cell Mol Physiol. 2017-4-1
Curr Pharmacol Rep. 2016-4